Developing new drugs to reduce the harmful effects of parathion exposure
Advanced Development of Drugs to Mitigate Parathion Intoxication
This study is testing a new drug that might help protect people from the harmful effects of a dangerous insecticide called parathion, and it's for anyone who might be at risk of poisoning from this chemical.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10471251 on NIH RePORTER |
What this research studies
This research focuses on creating innovative therapies to lessen the health risks associated with acute exposure to parathion, a dangerous insecticide. The approach involves inhibiting the metabolism of parathion into its toxic form, paraoxon, using a candidate drug that has shown promise in reducing toxicity in preliminary studies. The drug is already undergoing clinical trials for other conditions, and the research aims to evaluate its effectiveness in preventing parathion-related harm in animal models. If successful, this could lead to new treatment options for individuals affected by organophosphate poisoning.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been exposed to parathion or are at risk of exposure to organophosphate insecticides.
Not a fit: Patients who have not been exposed to parathion or similar organophosphate compounds may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that significantly reduces mortality and morbidity from parathion exposure.
How similar studies have performed: Previous research has shown success with similar approaches in mitigating toxicity from other organophosphate compounds, indicating potential for this novel treatment.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Laskin, Jeffrey D — Rutgers Biomedical and Health Sciences
- Study coordinator: Laskin, Jeffrey D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.